Oral Peptide Sustains Ulcerative Colitis Improvements Through 76 Weeks
Icotrokinra maintained remission in many patients continuing treatment for 76 weeks, but incomplete safety and dropout data limit conclusions.
Summary
An oral drug called icotrokinra showed lasting benefits for adults with moderately to severely active ulcerative colitis, a disease that causes inflammation in the colon. In an initial randomized trial, 55% to 63% of patients receiving the drug improved by week 12, compared with 27% receiving placebo. Among patients who remained on treatment through week 76, approximately 56% to 59% were in remission, and examinations showed reduced inflammation in many participants. The drug blocks a receptor involved in inflammation and could eventually offer an alternative to injected treatments. However, the long-term findings describe patients continuing treatment, which can make results look better if nonresponders leave. The supplied article also lacks detailed safety results and dropout information. These promising findings do not establish long-term safety or approval for ulcerative colitis.
Detailed Summary
Ulcerative colitis causes recurring inflammation in the colon that can disrupt daily life and require prolonged treatment. An experimental oral peptide called icotrokinra blocks the receptor for an inflammatory signal called interleukin 23. Researchers reported that many patients who remained on treatment maintained improvements through 76 weeks, suggesting a potential alternative to injected therapies.
The phase IIb ANTHEM-UC trial tested doses of 100, 200, and 400 milligrams in adults with moderately to severely active disease. At week 12, clinical response rates were 55%, 58%, and 63%, respectively, compared with 27% for placebo. All three comparisons met statistical significance, supporting an early treatment effect.
During the extension, patients remaining on treatment had response rates of approximately 73% to 81% at week 76. Clinical remission rates ranged from about 56% to 59%, while examinations of the colon showed improvement in approximately 64% to 68%. The report states that 97% of patients in remission were not taking corticosteroids. Symptom remission appeared as early as week four.
These findings suggest that targeted inflammation control may remain effective over time in patients who continue therapy. Patients without prior advanced treatment generally responded better, although previously treated patients also achieved remission. If approved for ulcerative colitis, an oral option could expand treatment choices. Patients should discuss established therapies and clinical trials with their gastroenterologist rather than change medications independently.
However, the long-term results come from a conference presentation summarized in a news article, and the supplied text is incomplete. Outcomes among patients remaining on treatment can overestimate benefits if patients with poor responses discontinued. The excerpt provides no detailed safety results, dropout counts, or long-term placebo comparison. Larger controlled trials and complete safety data are needed before judging comparative effectiveness, uncommon harms, or whether these benefits will persist across the broader adult ulcerative colitis patient population.
Key Findings
- At week 12, clinical response reached 55%–63% with icotrokinra versus 27% with placebo across three tested doses.
- Among patients remaining on treatment at week 76, approximately 56%–59% achieved clinical remission.
- Colon examinations showed improvement in approximately 64%–68% of patients continuing treatment through week 76.
- Long-term results require caution because the excerpt lacks dropout counts, detailed safety findings, and a concurrent placebo comparison.
- Discuss treatment options with a gastroenterologist; these findings do not establish approval for ulcerative colitis.
Methodology
This is a MedPage Today medical news report covering a conference presentation of the phase IIb ANTHEM-UC extension. It also summarizes earlier randomized, placebo-controlled findings reportedly published in the New England Journal of Medicine; the extension findings should be checked against the full abstract and eventual peer-reviewed publication.
Study Limitations
The supplied article ends mid-sentence and omits complete enrollment, retention, adverse-event, and statistical-analysis details. Reporting outcomes among patients remaining on treatment creates potential selection bias, and the excerpt does not establish comparative long-term effectiveness or safety.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: